Who Owns Eurobio Scientific Company?

Eurobio Scientific Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Eurobio Scientific?

Understanding Eurobio Scientific's ownership is key to grasping its strategic direction. A 2024 tender offer significantly reshaped its ownership, with investment funds now holding a majority stake.

This shift highlights how ownership changes can profoundly impact a company's market position and future trajectory.

Eurobio Scientific, a French group in in vitro diagnostics and life sciences, was founded in 1997. It specializes in developing, manufacturing, and marketing diagnostic tests for areas like infectious diseases and oncology, alongside distributing products from international partners. The company's journey began with a vision to establish a strong presence in specialized diagnostics, a goal pursued through both internal product development and strategic partnerships. For a deeper dive into its operational environment, consider the Eurobio Scientific PESTEL Analysis.

As of August 2025, Eurobio Scientific, listed on Euronext Growth Paris, has a market capitalization of approximately $291 million USD. In 2024, the company reported revenues of €154.2 million, a 19% increase year-over-year, with a net income of €4 million. This analysis will explore the evolution of its ownership, focusing on key leaders, major investors, and recent trends concentrating control.

Eurobio Scientific's ownership journey began in 1997 under the name Diaxonhit. While the precise initial founder equity is not detailed, key individuals shaped its trajectory, notably Jean-Michel Carle Grandmougin. His involvement, particularly with the EUROBIO / Capforce Group acquisition in March 2017, was pivotal, leading to the company's rebranding as Eurobio Scientific in June 2018.

Founding Entity

The company originated in 1997 under the name Diaxonhit. Early ownership details are not extensively publicized.

Key Leadership Influence

Jean-Michel Carle Grandmougin played a crucial role, particularly through the acquisition of the EUROBIO / Capforce Group.

Strategic Acquisition

The March 2017 acquisition of EUROBIO / Capforce Group was a transformative event for the company's structure and identity.

Rebranding Milestone

The company adopted the Eurobio Scientific name in June 2018, marking a new chapter post-acquisition.

Early Backers

Information on early angel investors or other initial backers beyond key operational figures is not readily available in current public disclosures.

Founding Vision

The early vision of the founding team centered on establishing a comprehensive player in specialty diagnostics.

The early ownership structure of Eurobio Scientific, tracing back to its 1997 inception as Diaxonhit, is not extensively detailed in terms of precise founder shareholdings. However, the strategic direction and eventual rebranding were significantly influenced by key figures. Jean-Michel Carle Grandmougin, with over 35 years in in vitro diagnostics, held leadership positions including President of the Management Board of the DIAXONHIT Group from 2017 and later Chairman and CEO from 2019. His prior role as a partner in the EUROBIO / Capforce Group, which Diaxonhit acquired in March 2017, was a critical step. This acquisition integrated substantial capabilities and led to the company's adoption of the Eurobio Scientific name in June 2018, a move that reshaped its corporate identity and ownership landscape. Early investment rounds and the specific contributions of initial backers beyond these central figures are not widely disclosed in public financial reports. The foundational strategy, solidified through the Diaxonhit and Eurobio/Capforce integration, aimed to build a robust entity in specialty diagnostics, a goal that continues to guide its strategic acquisitions and product development efforts. Understanding the Target Market of Eurobio Scientific provides context for its strategic evolution.

Founders and Early Ownership Dynamics

The evolution of Eurobio Scientific's ownership is marked by key strategic moves and leadership transitions rather than a clearly defined initial ownership breakdown.

• The company began as Diaxonhit in 1997.
• Jean-Michel Carle Grandmougin was a pivotal figure, influencing strategic direction.
• The acquisition of EUROBIO / Capforce Group in March 2017 was a significant ownership consolidation event.
• The company rebranded to Eurobio Scientific in June 2018.
• Detailed information on early angel investors or initial equity splits remains limited in public disclosures.

Eurobio Scientific SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Eurobio Scientific's ownership structure underwent a significant transformation in 2024, moving from a publicly traded company with a dispersed shareholder base to one with concentrated control. This shift was primarily driven by a voluntary public tender offer that consolidated majority ownership under strategic investment firms.

The evolution of Eurobio Scientific's ownership began with its IPO on Euronext Growth Paris on November 17, 2005. By January 11, 2024, the company had 10,248,871 shares outstanding, each with a nominal value of €0.32. The pivotal moment in its ownership history occurred in 2024 when EB Development, a holding company supported by IK Partners and NextStage AM, successfully acquired a substantial majority stake. This acquisition, which resulted in EB Development holding 88.9% of the capital by December 2024, was a result of a voluntary public tender offer and received approval from the European Commission. This consolidation of control by IK Partners and NextStage AM signifies a strategic move to enhance the company's position in the pharmaceutical diagnostic products and services market, aligning with the broader Growth Strategy of Eurobio Scientific. Other institutional holders, as of October 2024, included Amplegest SAS at 1.17%, SICAV PLACEURO (Conseil) S.A. at 0.50%, Keren Finance at 0.40%, MCA Finance at 0.31%, and Groupama Asset Management SA at 0.12%.

Key Stakeholders in Eurobio Scientific

The current ownership structure of Eurobio Scientific is largely dominated by investment firms following a significant tender offer in 2024.

• EB Development, backed by IK Partners and NextStage AM, is the majority owner with 88.9% of the capital as of December 2024.
• This consolidation represents a shift towards concentrated control by private equity and asset management firms.
• IK Partners is a Luxembourg-based private equity firm, and NextStage AM is a French asset management firm.
• The European Commission approved the joint control acquisition by IK Partners and NextStage AM.

Eurobio Scientific PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Eurobio Scientific Board of Directors is comprised of individuals holding key executive positions and representatives of significant shareholders, ensuring a blend of operational insight and investor representation. As of 2025, the board includes executive leadership and independent directors, reflecting a commitment to robust corporate governance.

The voting power within Eurobio Scientific is significantly influenced by the recent tender offer by EB Development, which by December 2024 had secured an impressive 88.9% stake. This substantial ownership by EB Development, backed by IK Partners and NextStage AM, positions them as the dominant force in strategic decision-making and board appointments. Consequently, major resolutions, including those passed at the Annual General Meeting on June 19, 2025, are expected to align closely with the interests of these primary Eurobio Scientific shareholders.

Understanding Eurobio Scientific's Corporate Structure

The Eurobio Scientific company structure is largely defined by its majority owner following a recent tender offer. This consolidation of ownership has a direct impact on the company's strategic direction and governance.

• EB Development holds a significant majority stake of 88.9% as of December 2024.
• IK Partners and NextStage AM are key investors influencing strategic decisions.
• The board composition includes executive leadership and independent directors.
• The voting power is concentrated, aligning with the majority Eurobio Scientific shareholders.
• Understanding the Mission, Vision & Core Values of Eurobio Scientific can provide context to their strategic direction.

Eurobio Scientific Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Eurobio Scientific's ownership landscape has seen a significant shift in recent years, culminating in a substantial change in its majority ownership. This transformation is a direct result of strategic maneuvers aimed at consolidating its market position and driving future growth.

The recent tender offer in 2024, which saw EB Development, a consortium associated with IK Partners and NextStage AM, acquire a commanding 88.9% of Eurobio Scientific's capital by December 2024, marks a pivotal moment in the company's ownership structure. This concentration of ownership aligns with a broader industry trend of consolidation, often facilitated by private equity firms looking to accelerate strategic development and operational efficiencies. The company's active acquisition strategy over the past three to five years, including key deals like the purchase of the EndoPredict® and Prolaris® oncology business from Myriad Genetics in August 2024 and the Life Science unit of Voden Medical Instruments S.p.A. by July 1, 2025, underscores its commitment to expanding its market footprint and diversifying its revenue streams. These strategic moves have contributed to a notable revenue increase, with reported figures reaching €154.2 million in 2024, a 19% rise from the previous year. Eurobio Scientific's stated strategy, as detailed in its 2024 annual results, emphasizes the development of proprietary products, international expansion, and entry into new markets, with an ambition for proprietary offerings to account for approximately 50% of revenues within the next five years. This focus, coupled with the consolidated ownership, suggests a streamlined approach to executing its long-term vision, as further explored in the Revenue Streams & Business Model of Eurobio Scientific.

Majority Ownership Consolidation

EB Development's acquisition of nearly 89% of Eurobio Scientific's capital in 2024 signifies a strong consolidation of ownership. This move by private equity-linked entities aims to bolster strategic execution and growth initiatives.

Strategic Acquisition Drive

The company has actively expanded its portfolio through significant acquisitions, including key oncology assets and life science units. These acquisitions are central to its revenue growth and market penetration strategy.

Focus on Proprietary Products

Eurobio Scientific is strategically shifting towards developing its own proprietary products. The company aims for these products to represent about 50% of its revenue within five years.

Revenue Growth and Expansion

In 2024, the company achieved revenue of €154.2 million, marking a 19% increase year-over-year. This growth is attributed to its strategic acquisitions and internationalization efforts.

Eurobio Scientific Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔